Design and baseline characteristics of SALT-HF trial : hypertonic saline therapy in ambulatory heart failure
Cobo Marcos, M. (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Comín-Colet, Josep (Hospital Universitari de Bellvitge)
De la Espriella, Rafael (Universitat de València)
Rubio Gracia, J. (Universidad de Zaragoza)
Morales-Rull, J.L. (Institut de Recerca Biomèdica)
Zegrí-Reiriz, Isabel (Institut de Recerca Sant Pau)
Llacer, P. (Universidad de Alcalá)
Diez-Villanueva, P. (Hospital Universitario de la Princesa (Madrid))
Jiménez-Marrero, S. (Hospital Universitari de Bellvitge)
de Juan Bagudá, J. (Universidad Europea de Madrid)
Ortiz Cortés, C. (Hospital Universitario San Pedro de Alcántara)
Goirigolzarri-Artaza, J. (Hospital Clínico San Carlos (Madrid))
García Pinilla, José Manuel (Insitituto de Salud Carlos III)
Barrios, E. (Hospital Universitario Rey Juan Carlos (Madrid))
del Prado Díaz, S. (Hospital Universitario Ramón y Cajal (Madrid))
Montero Hernández, E. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Sanchez-Marteles, M. (Universidad de Zaragoza)
Nuñez, J. (Hospital Clínic Universitari (València))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Hypertonic saline solution (HSS) plus intravenous (IV) loop diuretic appears to enhance the diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this therapy in the ambulatory setting have not been evaluated. We aimed to describe the design and baseline characteristics of the SALT-HF trial participants. 'Efficacy of Saline Hypertonic Therapy in Ambulatory Patients with HF' (SALT-HF) trial was a multicenter, double-blinded, and randomized study involving ambulatory patients who experienced worsening heart failure (WHF) without criteria for hospitalization. Enrolled patients had to present at least two signs of volume overload, use ≥ 80 mg of oral furosemide daily, and have elevated natriuretic peptides. Patients were randomized 1:1 to treatment with a 1-h infusion of IV furosemide plus HSS (2. 6-3. 4% NaCl depending on plasmatic sodium levels) versus a 1-h infusion of IV furosemide at the same dose (125-250 mg, depending on basal loop diuretic dose). Clinical, laboratory, and imaging parameters were collected at baseline and after 7 days, and a telephone visit was planned after 30 days. The primary endpoint was 3-h diuresis after treatment started. Secondary endpoints included (a) 7-day changes in congestion data, (b) 7-day changes in kidney function and electrolytes, (c) 30-day clinical events (need of IV diuretic, HF hospitalization, cardiovascular mortality, all-cause mortality or HF-hospitalization). A total of 167 participants [median age, 81 years; interquartile range (IQR), 73-87, 30. 5% females] were randomized across 13 sites between December 2020 and March 2023. Half of the participants (n = 82) had an ejection fraction.
Ajuts:	Instituto de Salud Carlos III PI20/00689
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diuretic resistance ; Hypertonic saline solution ; Hypertonic therapy ; Outpatient with heart failure
Publicat a:	ESC Heart Failure, Vol. 11 Núm. 3 (june 2024) , p. 1767-1776, ISSN 2055-5822

DOI: 10.1002/ehf2.14720
PMID: 38380837

10 p, 520.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats